Please login to the form below
Pronova
This page shows the latest Pronova news and features for those working in and with pharma, biotech and healthcare.
FDA approves AZ’s fish oil drug
Once launched Epanova will enter a competitive for market for hypertriglyceridemia medicines, including BASF/Pronova's Omacor/Lovaza, another omega-3 fatty acid product.
Latest news
-
Teva launches first generic of GSK's Lovaza in US
GSK acquired US rights to Lovaza - which was originally developed by Norway's Pronova BioPharma - when it took over Reliant Pharmaceuticals in 2008 for $1.7bn. ... An earlier settlement between ProNova and Apotex gave the generics company rights to
-
AZ target Omthera files blood fat drug in US
There is competition in the hypertriglyceridemia area, however, and if approved, Epanova would compete in the marketplace against BASF/Pronova's Omacor/Lovaza, an omega-3 fatty acid product that achieved
-
AstraZeneca offers $443m to buy Omthera
weeks. If approved, Epanova would compete in the marketplace against BASF/Pronova's Omacor/Lovaza, an omega-3 fatty acid product that achieved end-user sales of around $1.4bn in
-
Early 2013 sees drug filings, launches and approvals in Japan
originator Pronova BioPharma of Norway.
-
GSK acquires Reliant Pharmaceuticals
The drug, the US rights of which were in-licensed from Norway-based Pronova BioPharma, is indicated as an adjunct to diet. ... Pronova will continue to supply the product's primary material. Rights to Lovaza in other markets have been licensed by the
More from news
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Pharma deals during November 2012
that corresponds to a 24 per cent premium on Pronova's average six month share price and values the company at about 5.7 times annual earnings. ... 900. Pronova BioPharma / BASF. Acquisition. Omega-3 fatty acids. Active ingredient for Lovaza, p
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- First trial of a vaccine against Alzheimer’s launches
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- AbbVie/Allergan merger faces renewed public opposition despite divestments
- AbbVie/Allergan's merger faces public opposition
- AstraZeneca officially opens new R&D facility in UK
PMHub
KVA Digital
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
